

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 September 2020 (10.09.2020)



(10) International Publication Number
WO 2020/180591 A1

(51) International Patent Classification:

A61K 39/00 (2006.01) C07K 16/28 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2020/020042

(22) International Filing Date:

27 February 2020 (27.02.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/812,585 01 March 2019 (01.03.2019) US
62/969,976 04 February 2020 (04.02.2020) US

(71) Applicants: **ALLOGENE THERAPEUTICS, INC.**
[US/US]; 210 E. Grand Avenue, South San Francisco, California 94080 (US). **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors: **ZHANG, Yi**; c/o Allogene Therapeutics, Inc., 210 E. Grand Avenue, South San Francisco, California 94080 (US). **VAN BLARCOM, Thomas John**; c/o Allogene Therapeutics, Inc., 210 E. Grand Avenue, South San Francisco, California 94080 (US). **PANOWSKI, Siler**; c/o Allogene Therapeutics, Inc., 210 E. Grand Avenue, South San Francisco, California 94080 (US). **TACHEVA-GRIGOROVA, Silvia K.**; c/o Allogene Therapeutics, Inc., 210 E. Grand Avenue, South San Francisco, California 94080 (US). **SASU, Barbra Johnson**; c/o Allogene Therapeutics, Inc., 210 E. Grand Avenue, South San Francisco, California 94080 (US).

(74) Agent: **CHANG, Y. Elaine** et al.; Allogene Therapeutics, Inc., 210 E. Grand Avenue, South San Francisco, California 94080 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

WO 2020/180591 A1

(54) Title: DLL3 TARGETING CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS

(57) Abstract: Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs.